Enhertu bests key Roche rival in major breast cancer trial
AstraZeneca (LSE: AZN) and Daiichi Sankyo (TSE: 4568) have unveiled new Phase III results showing that Enhertu (trastuzumab deruxtecan) outperformed Roche’s (ROG: SIX) Kadcyla (trastuzumab emtansine) in patients with high-risk HER2-positive early breast cancer.
The DESTINY-Breast05 study met its primary endpoint, with Enhertu delivering a significant gain in invasive disease-free survival.
The trial involved patients who still had invasive disease after neoadjuvant therapy and surgery, a group considered at particularly high risk of recurrence. Overall survival was not mature at this interim stage, and the companies said further follow-up is planned. Safety findings were consistent with the established profile of Enhertu.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze